Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)

PHASE2RecruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

June 2, 2023

Primary Completion Date

February 5, 2026

Study Completion Date

February 5, 2026

Conditions

Brain Metastases

Interventions

DRUG

Niraparib

Given by PO

DRUG

Dostarlimab

Given by IV (vein)

Trial Locations (1)

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER